Compare Coinbase Global, Inc. (COIN) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coinbase Global, Inc. vs Gilead Sciences, Inc. — how do they compare? Coinbase Global, Inc. trades at $149.3 (market cap $39.20B), while Gilead Sciences, Inc. trades at $136.32 (market cap $168.35B). The key difference: Gilead Sciences, Inc. is far larger — about 4.3× Coinbase Global, Inc.'s market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Coinbase Global, Inc. pays none. Which is the better fit depends on your goals.
| COIN | GILD | |
|---|---|---|
Market Cap | $39.20B | $168.35B |
Sector | Technology | Health |
52-Week High | $387.27 | $155.80 |
52-Week Low | $141.09 | $110.56 |
Enterprise Value | $36.85B | $191.42B |
Dividend Yield | — | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COIN trades at $150.35, up 1.12% with bearish technical signals but strong analyst support (55% buy ratings). The company reported mixed Q2 2026 results with revenue and EPS misses, though it achieved a record 10.3% global trading volume share. Fundamentals show revenue growth from $3.1B in 2023 to $7.2B in 2025, but profitability remains volatile with recent quarterly losses.
The stock faces near-term pressure from earnings misses and crypto market volatility, but long-term potential exists through business diversification beyond retail trading. Key risks include competitive threats and regulatory uncertainty, while the $207.20 consensus price target suggests 38% upside if execution improves.
Gilead Sciences (GILD) trades at $135.78, up 2.04% on the day, with a bullish technical signal and strong support at $134. Recent Q2 2026 earnings beat revenue estimates despite a net loss, driven by 10% base business growth from HIV drugs like Biktarvy. The company raised its full-year sales outlook, but faces a negative net income margin of -10.64% and elevated debt levels.
The outlook is mixed: robust HIV franchise growth and a 67% analyst buy rating support upside to the $151.22 consensus target, but acquisition costs, patent cliff risks, and volatile cash flows pose challenges. Investment appeal hinges on pipeline execution offsetting margin pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Coinbase Global, Inc.
Coinbase Global, Inc. is a regulated cryptocurrency company that provides customers around the world with a platform for buying, selling, transferring, and storing digital assets. The Company offers a variety of products and services that enable individuals, businesses, and developers to participate in the cryptoeconomy.
Read more on COIN →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
